ABL Diagnostics adds TEXCELL assets to expand viral safety capabilities

ABL Diagnostics said it has acquired TEXCELL’s activities and assets, adding patented viral safety technology and broader virology and bacteriology expertise. The deal expands the French diagnostics company beyond pathogen detection into sample and biological product safety as biopharma demand and biosafety requirements rise.

Why it matters: - ABL Diagnostics is expanding beyond molecular diagnostics into viral safety, a field tied to the development and production of vaccines, biological medicines, viral vectors, and cell and gene therapies. - The added capabilities could broaden ABL Diagnostics’ reach with laboratories, biotechnology companies, and pharmaceutical customers that need to detect, quantify, eliminate, and inactivate infectious agents. - The acquisition also strengthens ABL Diagnostics’ intellectual property portfolio and creates new product, service, and technology opportunities in life sciences.

What happened: - ABL Diagnostics announced the acquisition of TEXCELL’s activities and assets in Woippy, France, on Sept. 10, 2026. - The transaction adds strategic expertise in viral safety to ABL Diagnostics’ existing molecular diagnostics business. - The company is also adding new products, technologies, and services in virology and bacteriology focused on sample safety, sample preparation, and biological products.

The details: - Among the acquired assets is a patented technology based on patent application EP 10306347.5. - The technology is designed to quantify infectious viruses using reference infectious standards. - The method enables quantitative assessment of viral infectivity through host-cell response. - The technology has potential for automation and high-throughput processing. - ABL Diagnostics says the new capability adds viral-risk assessment and management to its existing ability to detect, identify, and characterize infectious agents. - TEXCELL’s Sales Manager Mohammed Errafyqy said the combined expertise addresses a broader value chain, from sample and biological product safety to pathogen detection and characterization. - ABL Diagnostics said the acquisition complements its longstanding positioning in molecular diagnostics and infectious diseases. - The company said its broader portfolio now spans viral safety, virology, and bacteriology.

Between the lines: - The acquisition fits a market where biosafety and quality requirements are getting tighter across biopharma. - ABL Diagnostics appears to be moving up the value chain, from identifying pathogens to helping customers manage upstream biological risk. - The deal may also help ABL Diagnostics sell into regulated workflows where safety testing and molecular analysis are increasingly linked.

What's next: - ABL Diagnostics said the combined expertise should support new opportunities with laboratories and the biopharmaceutical industry. - The company expects the expanded technology base to support future products, services, and technological developments. - ABL Diagnostics said its life sciences activities will also now include virology, biosafety testing, and biopharmaceutical development expertise. - The company continues to market its existing product lines worldwide through its own sales team and exclusive distributors.

The bottom line: - The TEXCELL acquisition gives ABL Diagnostics a bigger role in both detecting infectious agents and helping ensure biological product safety.